Sponsors (3)
The bill creates structured, transparent expert-stakeholder meetings to accelerate and clarify rare-disease drug development and increase accountability, but it risks industry influence, partial transparency due to trade secrets, and diverting FDA resources for a modest federal cost.
Patients with rare diseases: will get clearer, more predictable pathways for developing new treatments through regular expert-stakeholder meetings that can speed decision-making and reduce uncertainty.
Drug sponsors, researchers, and small biotech firms: gain predictable forums to align on trial design, endpoints, and biomarkers, which can reduce development delays and lower technical barriers to bringing therapies forward.
Patients, providers, and the public: will have improved access to meeting information because transcripts, recordings, and summaries (including consensus and next steps) must be posted publicly within 180 days, increasing transparency of deliberations.
Patients with rare diseases and advocacy groups: risk that industry participation in steering and meetings will bias discussions toward commercially viable approaches rather than patient-prioritized needs or less profitable options.
Patients, hospitals, and researchers: FDA staff time devoted to these meetings may increase workload and divert agency resources from other review tasks, potentially slowing other regulatory reviews or oversight activities.
Patients, providers, and researchers: public postings may still exclude confidential commercial or trade-secret information, meaning some deliberations will remain opaque and full transparency will be limited.
Based on analysis of 2 sections of legislative text.
Requires HHS to create externally led, science-focused drug development meetings for rare diseases, run by the Reagan-Udall Foundation with a permanent steering committee and at least four meetings yearly.
Introduced February 24, 2025 by Doris Matsui · Last progress February 24, 2025
Creates a new HHS process for externally led, science-focused drug development (EL–SFDD) meetings to help experts, drug sponsors, patient groups, and regulators align on scientific and regulatory questions for rare diseases. Directs HHS to contract with the Reagan-Udall Foundation to convene at least four EL–SFDD meetings per year, and requires the Foundation to run a permanent multistakeholder steering committee to select and recommend meeting topics using defined criteria.